Douglas Sheridan

Douglas Sheridan, PhD has over 10 years of experience in the biopharmaceutical industry. In 2019, they became the R&D Program Lead at Rallybio. Prior to that, they were at Alexion Pharmaceuticals, Inc. from 2008 to 2019, where they held several roles, including Global Program Team Leader, ALXN1210 SC and ALXN1810 SC, Executive Director, ALXN1210 Subcutaneous Clinical Development Team Leader, Senior Director, Early Development Team Leader, Senior Director, Discovery Research, Director and Head of Molecular Sciences, Associate Director of Molecular Sciences, and Senior Staff Scientist, Protein Sciences. In their roles, Dr. Sheridan managed all activities for the discovery, engineering and preclinical development of new therapeutic candidates, identified targets and modalities, contributed to company strategies on complement therapeutics, chaired scientific review committees, created Alexion's Postdoctoral Program, and managed teams of Ph.D. and M.Sc. level scientists.

Douglas Sheridan, PhD obtained their Doctor of Philosophy (Ph.D.) in Neuroscience from Yale University between 2000 and 2004. Prior to that, they earned a Bachelor of Science (B.Sc.) in Biochemistry and Molecular Biology from Penn State University between 1997 and 2000.